London: Global experts are urging a shift in how obesity is diagnosed and treated, calling for a more accurate and nuanced definition that goes beyond the traditional body mass index (BMI) measurement.
The report, published in The Lancet Diabetes & Endocrinology and supported by over 50 international medical professionals, emphasizes evaluating overall health rather than relying solely on BMI, which fails to differentiate between muscle and fat or account for harmful fat around the waist and organs.
BMI: A flawed metric
Key recommendations include categorizing individuals with weight-related chronic illnesses as having ‘clinical obesity,’ requiring drug treatments, while those without significant health issues but at future risk are identified as having ‘pre-clinical obesity.’ This group would benefit from weight-loss advice, counseling, monitoring, and potentially non-invasive treatments.
Obesity, currently defined in many countries as a BMI over 30, affects over a billion people worldwide. However, BMI provides a “blurry picture,” says report chair Prof. Francesco Rubino of King’s College London, who advocates for “reframing” obesity to reflect varying levels of health risks. Waist-height ratios, direct fat measurement, and detailed medical histories could offer a clearer and more individualized diagnosis.
Improved Care
The report highlights the importance of this approach amid rising demand for weight-loss drugs like Wegovy and Mounjaro, which can reduce body weight by up to 20%. Experts caution against unnecessary treatment, particularly for individuals without significant health issues, and stress early intervention for those at risk.
Children’s obesity expert Prof. Louise Baur, from the University of Sydney, notes the proposed model would provide more tailored care while minimizing over-diagnosis. The Royal College of Physicians commended the report, calling the distinction between pre-clinical and clinical obesity a “vital step forward.”
Despite the potential benefits, concerns remain about limited healthcare budgets prioritizing treatment for clinically obese patients over preventive measures. Prof. Sir Jim Mann of New Zealand’s Edgar Diabetes and Obesity Research Centre warns that funding constraints could shift focus away from those in the pre-clinical category, despite the long-term benefits of early care.
This nuanced approach aims to balance precise diagnosis with appropriate resource allocation, addressing the global challenge of obesity more effectively.
ALSO READ | UK launches ‘AI Action Plan’ to transform lives and drive change
